Efficacy of vitamin D supplementation among persons living with HIV/AIDS in São Paulo city, Brazil.
Brazil
HIV
Vitamin D deficiency
supplementation
Journal
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
ISSN: 1678-4391
Titre abrégé: Braz J Infect Dis
Pays: Brazil
ID NLM: 9812937
Informations de publication
Date de publication:
Historique:
received:
02
03
2021
revised:
31
05
2021
accepted:
13
06
2021
pubmed:
20
7
2021
medline:
1
9
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
Hypovitaminosis D is now considered a pandemic, especially among more vulnerable populations and in HIV-infected subjects, with 80% presenting levels below 30 ng/mL. As there is no consensus on the more adequate dosage needed to correct such deficiency, the objective of this study was to evaluate 25 (OH) vitamin D supplementation in HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients were randomized to the active group, supplemented once a week with 50,000 UI vitamin D by mouth (group 1) and 36 to the placebo group (group 2). The study period ranged from June 2016 to September 2017. Variables involved in vitamin D metabolism and risk factors associated with hypovitaminosis were evaluated. The mean age was 45 years and 31.5 % were women. Vitamin D supplementation was effective in normalizing serum levels after six months in group 1 (mean 35 ng/mL compared to 21 ng/mL for the placebo group; p = 0.04). No patient reached blood levels considered toxic (>100 UI). Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. A weekly oral dose of 50,000 IU of vitamin D was sufficient to normalize the vitamin deficiency, safely and with good adherence among persons living with HIV/AIDS in Brazil.
Identifiants
pubmed: 34280356
pii: S1413-8670(21)00067-2
doi: 10.1016/j.bjid.2021.101598
pmc: PMC9392205
pii:
doi:
Substances chimiques
Vitamin D
1406-16-2
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
101598Informations de copyright
Copyright © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare no conflicts of interest
Références
Arq Bras Endocrinol Metabol. 2008 Apr;52(3):482-8
pubmed: 18506273
Arch Endocrinol Metab. 2017 Jan-Feb;61(1):21-27
pubmed: 27737331
Pediatr Infect Dis J. 2015 Feb;34(2):e32-40
pubmed: 24988118
Sci Rep. 2015 Aug 10;5:12990
pubmed: 26257370
Arch Endocrinol Metab. 2015 Feb;59(1):34-41
pubmed: 25926112
J Clin Endocrinol Metab. 2010 Feb;95(2):471-8
pubmed: 20133466
Rev Bras Reumatol. 2010 Jan-Feb;50(1):67-80
pubmed: 21125142
J Int AIDS Soc. 2020 Oct;23(10):e25624
pubmed: 33040465
PLoS Med. 2019 Sep 11;16(9):e1002907
pubmed: 31509529
Bone. 2008 Feb;42(2):246-9
pubmed: 18055288
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Bone Miner Res. 2011 Dec;26(12):2860-71
pubmed: 21915904
Osteoporos Int. 2009 Nov;20(11):1807-20
pubmed: 19543765
Top Antivir Med. 2012 Jun-Jul;20(2):48-60
pubmed: 22710907
Rev Endocr Metab Disord. 2017 Jun;18(2):153-165
pubmed: 28516265